Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Soccer-Chelsea confirm Mudryk contacted by FA over adverse sample
    Finance

    Soccer-Chelsea confirm Mudryk contacted by FA over adverse sample

    Published by Global Banking & Finance Review®

    Posted on December 17, 2024

    1 min read

    Last updated: January 27, 2026

    Image depicting soccer players engaged in a match, symbolizing the proposed Unity League by European Super League promoters. This initiative aims to reshape soccer's competitive landscape and address key financial issues in the sport.
    Soccer players in action, highlighting the European Super League's new Unity League concept - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Chelsea's Mykhailo Mudryk is under FA investigation for an adverse urine test. The club and player support the testing program and deny any wrongdoing.

    Chelsea's Mudryk Contacted by FA Over Adverse Sample

    LONDON (Reuters) - Chelsea have confirmed that forward Mykhailo Mudryk has been contacted by the Football Association after an adverse finding in a routine urine test.

    The Premier League club issued a brief statement on Tuesday confirming an investigation into the Ukraine international.

    "Both the Club and Mykhailo fully support The FA's testing programme and all our players, including Mykhailo, are regularly tested," the statement said.

    "Mykhailo has confirmed categorically that he has never knowingly used any banned substances. Both Mykhailo and the Club will now work with the relevant authorities to establish what has caused the adverse finding."

    Mudryk, who joined Chelsea in January 2023, has struggled for first-team opportunities this season and has largely been used as a substitute.

    (Reporting by Martyn Herman; Editing by Christian Radnedge)

    Key Takeaways

    • •Chelsea's Mudryk contacted by FA for adverse urine test.
    • •Club and player support FA's testing program.
    • •Mudryk denies knowingly using banned substances.
    • •Investigation to determine cause of adverse finding.
    • •Mudryk joined Chelsea in January 2023.

    Frequently Asked Questions about Soccer-Chelsea confirm Mudryk contacted by FA over adverse sample

    1What is the main topic?

    The main topic is the FA's investigation into Chelsea's Mykhailo Mudryk following an adverse urine test.

    2What is the club's stance?

    Chelsea and Mudryk fully support the FA's testing program and are cooperating with the investigation.

    3What has Mudryk stated?

    Mudryk has categorically denied knowingly using any banned substances.

    More from Finance

    Explore more articles in the Finance category

    Image for US wants Russia, Ukraine to end war by summer, Zelenskiy says
    US wants Russia, Ukraine to end war by summer, Zelenskiy says
    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    View All Finance Posts
    Previous Finance PostUK's FTSE 100 hits one-month low after pay data
    Next Finance PostKosmos Energy walks away from Tullow Oil acquisition